Meanwhile, targeted radionuclide therapy—for example, with Lutetium-177 (177Lu) labelled PSMA peptides—represents a promising treatment option for castration-resistant prostate cancer, as currently confirmed in the VISION study (ClinicalTrials.gov Identifier: NCT03511664) [17,18]. The gene discussed is FOLH1; the disease is prostate carcinoma.